Atea Pharmaceuticals (AVIR) Profit After Tax: 2019-2024
Historic Profit After Tax for Atea Pharmaceuticals (AVIR) over the last 6 years, with Dec 2024 value amounting to -$168.4 million.
- Atea Pharmaceuticals' Profit After Tax fell 129.40% to -$34.4 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$115.9 million, marking a year-over-year decrease of 195.64%. This contributed to the annual value of -$168.4 million for FY2024, which is 23.85% down from last year.
- As of FY2024, Atea Pharmaceuticals' Profit After Tax stood at -$168.4 million, which was down 23.85% from -$136.0 million recorded in FY2023.
- Over the past 5 years, Atea Pharmaceuticals' Profit After Tax peaked at $121.2 million during FY2021, and registered a low of -$168.4 million during FY2024.
- Moreover, its 3-year median value for Profit After Tax was -$136.0 million (2023), whereas its average is -$140.1 million.
- In the last 5 years, Atea Pharmaceuticals' Profit After Tax skyrocketed by 1,207.06% in 2021 and then tumbled by 195.64% in 2022.
- Yearly analysis of 5 years shows Atea Pharmaceuticals' Profit After Tax stood at -$10.9 million in 2020, then surged by 1,207.06% to $121.2 million in 2021, then crashed by 195.64% to -$115.9 million in 2022, then dropped by 17.30% to -$136.0 million in 2023, then decreased by 23.85% to -$168.4 million in 2024.